Skip to content

13F-HR filed by NOVO HOLDINGS A/S

NOVO HOLDINGS A/S filed this 13F-HR for the quarter ended 2025-06-30, filed 2025-08-14, with 29 holding rows worth $1,416,573,929.

Accession
0001415889-25-021889
Filed
2025-08-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2025

A holdings report, 29 entries on the cover page, a total value of $1,416,573,929 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,416,573,929 with VALUE read as dollars as filed, 13F file number 028-16231. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
VTI922908769COM1,038,550$315,646,502dollars as filed
BROOKFIELD CORP CL A LTD VT SH11271J107Stock2,330,830$144,161,836dollars as filed
ASMLHLDGNVFSPONSOREDADR1ADRREPS1ORDSHSN07059210STOK165,836$132,899,312dollars as filed
Salesforce.com, Inc79466L302COM330,187$90,038,693dollars as filed
MIRUM PHARMACEUTICALS INC604749101COM1,500,055$76,337,799dollars as filed
EDGEWISE THERAPEUTICS INC28036F105COM5,350,000$70,138,500dollars as filed
INSMED INC COM PAR $.01457669307Stock680,000$68,435,200dollars as filed
RECURSION PHARMACEUTICALS IN75629V104CL A9,665,128$48,905,548dollars as filed
CRINETICS PHARMACEUTICALS INC COM22663K107Stock1,550,000$44,578,000dollars as filed
ALIBABA GROUP HLDG LTD01609W102SPONSORED ADS372,327$42,225,605dollars as filed
ARRIVENT BIOPHARMA INC04272N102COM1,872,142$40,756,531dollars as filed
MERUS N VN5749R100COM750,000$39,450,000dollars as filed
BIOMARIN PHARMACEUTICAL INC09061G101COM660,000$36,280,200dollars as filed
BLUEPRINT MEDICINES CORP09627Y109COM264,956$33,962,060dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM2,380,000$33,272,400dollars as filed
PHARVARIS NVN69605108COMMON STOCK1,725,000$30,360,000dollars as filed
VAXCYTE INC COM92243G108Stock916,160$29,784,362dollars as filed
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW1,200,000$24,420,000dollars as filed
ZENAS BIOPHARMA INC COM98937L105Stock2,250,000$21,802,500dollars as filed
ENLIVEN THERAPEUTICS INC COM29337E102Stock1,084,432$21,753,706dollars as filed
APOGEE THERAPEUTICS INC COM03770N101Stock449,392$19,517,095dollars as filed
CERIBELL INC15678C102COMMON STOCK900,000$16,857,000dollars as filed
Valneva SE ADR92025Y103COM2,375,000$13,466,250dollars as filed
4D MOLECULAR THERAPEUTICS INC COM35104E100Stock2,000,000$7,420,000dollars as filed
IO BIOTECH INC449778109COM3,354,449$4,662,684dollars as filed
LANZATECH GLOBAL INC51655R101COM15,814,845$4,288,986dollars as filed
MARQETA INC57142B104CLASS A COM441,558$2,574,283dollars as filed
ABCELLERA BIOLOGICS INC COM00288U106Stock652,529$2,238,174dollars as filed
DAMORA THERAPEUTICS INC36322Q206COMMON STOCK99,913$340,703dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001415889-25-021889this filing2025-08-14acceptance time not in the bulk data set